QC Lab of the Future

The QC Lab of the future team are working on sharing common approaches and best practices to enable digitalization of the QC lab to maximize efficiency within the laboratory.

Technology advancements are not well supported

Quality control (QC) labs in the biopharmaceutical industry have fallen behind the digital enablement of the manufacturing environment. Test execution is not automated, partly because a lot of lab equipment cannot yet be controlled digitally. Technicians use non-integrated systems, often with fixed user interfaces based on reports and documentation/paper rather than individualized personal user experiences; they are not guided or assisted by technology. Data is not captured automatically or consistently, and it is not exposed for external usage in a standard format, making it very difficult to use analytics to optimize outcomes. This situation can also lead to significant data integrity concerns with regulatory agencies.

Technology advancements for at-line and in-line testing are not well supported. The QC lab of the future program sets out a manifesto of what things need to be improved, over a realistic three-year timeframe.

  • Getting everything ready for testing smoothly and efficiently
  • Automated testing with data capture
  • And managing that data

With about 50 topics, it is a big vision. Working in collaboration with lab equipment and software vendors on a shared vision for digital technology to form the basis of the QC lab of the future, our vision is that the lab of the future should leverage modern approaches and best practices to implement tools and technologies that maximize efficiency and performance of lab processes and operations.

Manifesto for improvement

Within that overall framework, the group has prioritized a set of topics to progress on collectively. Automation and data integration for lab equipment is the basis for many other capabilities. We’ve looked at different strategies for data aggregation and data integrity. There are many new opportunities (as well as challenges) with robots and cobots in the lab, and with augmented reality, virtual reality and speech interfaces leveraging AI technologies to assist users, create efficiencies, and increase ‘right first time’.

We are working to bring that manifesto to life in four ways:

Communicating it to the industry, a stake in the ground, a reference point.

Biomanufacturers are sharing their own strategies for their lab of the future, and working to align with each other and the manifesto – which makes them more credible, sustainable and thorough, and the alignment is needed if we are going to see industry-wide change.

Some key vendors to the lab are sharing their roadmaps and our question is “How are you going to take us towards this vision of the lab of the future”. It is a collaboration and we are starting to see change as they update and increase their digital enablement.

Finally, we are pushing forward some of the key topics, defining the design options, articulating benefits of change to all the stakeholders and looking at some of the new challenges – for example, next generation sequencing in the QC labs. Establishing common approaches is really important, particularly with the regulator. All of which help us progress with the QC lab of the future so that there is improved efficiency, performance and predictability, reducing the lead time on QC testing so we get closer to instant release. This could make a significant difference in the industry.

QC Lab of the Future deliverables


BioPhorum IT: Lab of the Future – Manifesto: digital technology-based capabilities for the quality control lab of the future

31 July, 2023Webinar

Lab of the Future: Manifesto: digital technology-based capabilities for the quality control (QC) lab of the future

30 July, 2023
1.31 MB

Data integrity challenges in the quality control (QC) labs

12 May, 2022
850.64 KB

The benefits of progressively more sophisticated lab instrument integration in the quality control labs

7 March, 2022
4.46 MB

More related workstreams

Our workstreams focus on the areas with the greatest impact across the industry. Led by science, our members are problem-solving today’s sustainability issues. By working with the regulatory governance community, they are also creating future-ready outcomes for the industry.

Contact BioPhorum

To find out more about how BioPhorum can help your business, enter your details below and a member of our team will be in touch.

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
Peer to peer practical guidance on remote inspections and audits
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing